Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Agonist anti-human CD27 monoclonal antibody induces T cell activation and tumor immunity in human CD27-transgenic mice.

He LZ, Prostak N, Thomas LJ, Vitale L, Weidlick J, Crocker A, Pilsmaker CD, Round SM, Tutt A, Glennie MJ, Marsh H, Keler T.

J Immunol. 2013 Oct 15;191(8):4174-83. doi: 10.4049/jimmunol.1300409. Epub 2013 Sep 11.

2.

Control of established melanoma by CD27 stimulation is associated with enhanced effector function and persistence, and reduced PD-1 expression of tumor infiltrating CD8(+) T cells.

Roberts DJ, Franklin NA, Kingeter LM, Yagita H, Tutt AL, Glennie MJ, Bullock TN.

J Immunother. 2010 Oct;33(8):769-79. doi: 10.1097/CJI.0b013e3181ee238f.

3.

Development of a human monoclonal antibody for potential therapy of CD27-expressing lymphoma and leukemia.

Vitale LA, He LZ, Thomas LJ, Widger J, Weidlick J, Crocker A, O'Neill T, Storey J, Glennie MJ, Grote DM, Ansell SM, Marsh H, Keler T.

Clin Cancer Res. 2012 Jul 15;18(14):3812-21. doi: 10.1158/1078-0432.CCR-11-3308. Epub 2012 May 15.

4.

4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy.

Cannons JL, Lau P, Ghumman B, DeBenedette MA, Yagita H, Okumura K, Watts TH.

J Immunol. 2001 Aug 1;167(3):1313-24.

5.

Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation.

French RR, Taraban VY, Crowther GR, Rowley TF, Gray JC, Johnson PW, Tutt AL, Al-Shamkhani A, Glennie MJ.

Blood. 2007 Jun 1;109(11):4810-5. Epub 2007 Feb 20.

6.

CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination.

Ahrends T, Bąbała N, Xiao Y, Yagita H, van Eenennaam H, Borst J.

Cancer Res. 2016 May 15;76(10):2921-31. doi: 10.1158/0008-5472.CAN-15-3130. Epub 2016 Mar 28.

7.

CD27 costimulation contributes substantially to the expansion of functional memory CD8(+) T cells after peptide immunization.

Taraban VY, Rowley TF, Kerr JP, Willoughby JE, Johnson PM, Al-Shamkhani A, Buchan SL.

Eur J Immunol. 2013 Dec;43(12):3314-23. doi: 10.1002/eji.201343579. Epub 2013 Oct 1.

8.

Ox40 costimulation enhances the development of T cell responses induced by dendritic cells in vivo.

De Smedt T, Smith J, Baum P, Fanslow W, Butz E, Maliszewski C.

J Immunol. 2002 Jan 15;168(2):661-70.

9.

Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.

Morales-Kastresana A, Sanmamed MF, Rodriguez I, Palazon A, Martinez-Forero I, Labiano S, Hervas-Stubbs S, Sangro B, Ochoa C, Rouzaut A, Azpilikueta A, Bolaños E, Jure-Kunkel M, Gütgemann I, Melero I.

Clin Cancer Res. 2013 Nov 15;19(22):6151-62. doi: 10.1158/1078-0432.CCR-13-1189. Epub 2013 Sep 12.

10.

Blockade of CD70-CD27 interaction inhibits induction of allergic lung inflammation in mice.

Makino F, Ito J, Abe Y, Harada N, Kamachi F, Yagita H, Takahashi K, Okumura K, Akiba H.

Am J Respir Cell Mol Biol. 2012 Sep;47(3):298-305. doi: 10.1165/rcmb.2011-0354OC. Epub 2012 Apr 12.

PMID:
22499851
11.

CD70 signaling is critical for CD28-independent CD8+ T cell-mediated alloimmune responses in vivo.

Yamada A, Salama AD, Sho M, Najafian N, Ito T, Forman JP, Kewalramani R, Sandner S, Harada H, Clarkson MR, Mandelbrot DA, Sharpe AH, Oshima H, Yagita H, Chalasani G, Lakkis FG, Auchincloss H Jr, Sayegh MH.

J Immunol. 2005 Feb 1;174(3):1357-64.

12.

Anti-tumor effects of depleting and non-depleting anti-CD27 monoclonal antibodies in immune-competent mice.

Sakanishi T, Yagita H.

Biochem Biophys Res Commun. 2010 Mar 19;393(4):829-35. doi: 10.1016/j.bbrc.2010.02.092. Epub 2010 Feb 18.

PMID:
20171165
13.

CD27 is required for generation and long-term maintenance of T cell immunity.

Hendriks J, Gravestein LA, Tesselaar K, van Lier RA, Schumacher TN, Borst J.

Nat Immunol. 2000 Nov;1(5):433-40.

PMID:
11062504
14.

Critical contribution of OX40 ligand to T helper cell type 2 differentiation in experimental leishmaniasis.

Akiba H, Miyahira Y, Atsuta M, Takeda K, Nohara C, Futagawa T, Matsuda H, Aoki T, Yagita H, Okumura K.

J Exp Med. 2000 Jan 17;191(2):375-80.

15.

CD8+ T cells produce the chemokine CXCL10 in response to CD27/CD70 costimulation to promote generation of the CD8+ effector T cell pool.

Peperzak V, Veraar EA, Xiao Y, Babala N, Thiadens K, Brugmans M, Borst J.

J Immunol. 2013 Sep 15;191(6):3025-36. doi: 10.4049/jimmunol.1202222. Epub 2013 Aug 12.

16.

Characterization of murine CD70 by molecular cloning and mAb.

Oshima H, Nakano H, Nohara C, Kobata T, Nakajima A, Jenkins NA, Gilbert DJ, Copeland NG, Muto T, Yagita H, Okumura K.

Int Immunol. 1998 Apr;10(4):517-26.

PMID:
9620608
17.

CD27-Mediated Regulatory T Cell Depletion and Effector T Cell Costimulation Both Contribute to Antitumor Efficacy.

Wasiuk A, Testa J, Weidlick J, Sisson C, Vitale L, Widger J, Crocker A, Thomas LJ, Goldstein J, Marsh HC, Keler T, He LZ.

J Immunol. 2017 Dec 15;199(12):4110-4123. doi: 10.4049/jimmunol.1700606. Epub 2017 Nov 6.

18.

In vivo administration of anti-murine CD3 monoclonal antibody induces selective, long-term anergy in CD8+ T cells.

Woodle ES, Hussein S, Bluestone JA.

Transplantation. 1996 Mar 15;61(5):798-803.

PMID:
8607186
19.
20.

Supplemental Content

Support Center